The MeTeOR trial has completed the recruitment and enrollment phase and is now in the follow-up and data analysis stages.
In 2010 the research team received additional funding and approval to extend the follow-up phase from 2 to 5 years (24 to 60 months) post treatment.
In August of 2012 all subjects who agreed had their extended follow-up (30-60 months) centralized to Brigham and Women’s Hospital (BWH). The BWH research team at OrACORe continues to follow all study subjects with questionnaires and imaging studies (radiographs and MRIs).
Currently, all subjects have completed at least 6 months of post treatment follow-up, and nearly all have passed the 1 year time point. The preliminary analysis of the 6 month trial results were presented at the 2012 American College of Rheumatology annual meeting in November in Washington, DC as well as the American Academy of Orthopedic Surgeons annual meeting the in spring of 2013.